Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1244435 | 0.99 | TLR7 (0.86) | TLR7 | |
| SCHEMBL9935661 | 0.91 | TLR7 (0.87) | TLR7 | |
| SCHEMBL18662251 | 0.88 | TLR7 (0.82) | TLR7 | |
| SCHEMBL1919072 | 0.87 | TLR7 (0.84) | TLR7 | |
| SCHEMBL1920965 | 0.86 | TLR7 (0.79) | TLR7 | |
| SCHEMBL1847376 | 0.86 | TLR7 (0.92) | TLR7 | |
| SCHEMBL1850014 | 0.86 | TLR7 (0.90) | TLR7 | |
| SCHEMBL1501648 | 0.85 | TLR7 (0.66) | TLR7 | |
| SCHEMBL1843707 | 0.85 | TLR7 (0.89) | TLR7 | |
| SCHEMBL567083 | 0.85 | TLR7 (0.98) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865896-B2 | Method for preparing adenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-10-21 | — | — | US | claimed |
| US-8865896-B2 | Method for preparing adenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-10-21 | — | — | US | disclosed |
| US-8865896-B2 | Method for preparing adenine compound | ASTRAZENECA AKTIEBOLAG (SE) | 2014-10-21 | — | — | US | disclosed |
| EP-2121693-B1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-8067411-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | disclosed |
| US-20110054168-A1 | METHOD FOR PREPARING ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110046369-A1 | METHOD FOR PREPARING ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-24 | — | — | US | disclosed |
| US-20110046369-A1 | METHOD FOR PREPARING ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2246353-A1 | METHOD FOR PRODUCING ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246353-A1 | METHOD FOR PRODUCING ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-2121693-A1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| WO-2008071976-A1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300244-A1 | NOVEL COMPOUNDS | NPY1R, F12, NPY2R | TLR7 3711/4885 |
| US-20110054168-A1 | METHOD FOR PREPARING ADENINE COMPOUND | ADORA3, ADORA1, NNMT | TLR7 336/4885 |
| US-20110046369-A1 | METHOD FOR PREPARING ADENINE COMPOUND | AMPD2, APRT, PARP2 | TLR7 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.